(Q35779915)

10 August 2017

1 reference

title

Atazanavir: new option for treatment of HIV infection (English)

1 reference

10 August 2017

1 reference

ChEBI release 2020-05-28

1

Diane V Havlir

1 reference

10 August 2017

Steven D O'Marro

2

1 reference

PubMed ID

15156449

10 August 2017

language of work or name

English

0 references

publication date

13 May 2004

1 reference

Clinical Infectious Diseases

10 August 2017

1 reference

10 August 2017

38

1 reference

10 August 2017

11

1 reference

10 August 2017

1599-1604

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

10 August 2017

1 reference

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

21 January 2018

1 reference

BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents

21 January 2018

1 reference

Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results

21 January 2018

1 reference

Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects

21 January 2018

1 reference

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

21 January 2018

1 reference

In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632

21 January 2018

1 reference

Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens

21 January 2018

1 reference

Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens

21 January 2018

1 reference

Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples

21 January 2018

1 reference

Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors

21 January 2018

1 reference

Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection

21 January 2018

1 reference

Combination antiretroviral therapy and the risk of myocardial infarction

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/420932

1 reference

10 August 2017

1 reference

PubMed ID

15156449